Occidental vs. Hess: Which Energy Stock Deserves a Spot in Your Folio?
The companies belonging to the Zacks Oil & Gas – Integrated - United States industry offer a strong investment case based on energy security, solid infrastructure, and supportive regulations. The U.S. shale boom has improved cost efficiency, scalable production, and access to top-tier pipelines and refineries, boosting profitability and resilience. U.S. companies are well-positioned to meet long-term domestic natural gas demand, driven by power generation and coal-to-gas transition, as well as rising LNG exports.These companies' selective overseas production activities offer valuable diversification and access to higher-margin barrels in specific regions, often through long-term production sharing agreements. This global presence helps mitigate risks from localized downturns or regulatory changes while enabling them to capitalize on growing demand in emerging markets. Amid such a backdrop, let us focus on Occidental Petroleum OXY and Hess Corporation HES as they are navigating through industry challenges to provide strong returns to investors.Occidental Petroleum is a strong investment opportunity, combining steady cash flow from its Permian Basin and global oil and gas assets with a growing focus on carbon management solutions. Supported by Berkshire Hathaway's backing, the company offers long-term value through its balanced approach to traditional energy production and scalable low-carbon technologies.Hess Corporation offers a compelling investment opportunity, underpinned by its strategic assets and commitment to sustainable growth. It is also proactively transitioning towards sustainable energy and has invested in renewable energy projects. These initiatives align with its goal to reduce greenhouse gas emissions and diversify its energy portfolio. HESS is undergoing a major transition with its pending acquisition by Chevron, which is currently under arbitration due to disputes over its Guyana assets.Both stocks mentioned above are the key operators in the Oil and Gas industry space. Let us dive deeper and closely compare the fundamentals of the two stocks to determine which is a better investment option for investors.
The Zacks Consensus Estimate for Occidental Petroleum's earnings indicates a year-over-year decline of 32.66% for 2025 and growth of 14.38% for 2026.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Hess Corporation's earnings indicates a year-over-year decline of 38.53% for 2025 and growth of 20.14% for 2026.
Image Source: Zacks Investment Research
Dividends are regular payments made by a company to its shareholders and represent a direct way for investors to earn a return on their investment. They are an important indicator of a company's financial health and stability, often signaling strong cash flow and consistent earnings.Currently, the dividend yield for Occidental Petroleum is 2.33%, while the same for Hess Corporation is 1.53%. The dividend yield of OXY is higher than the S&P 500's yield of 1.6%.
ROE is an essential financial indicator that evaluates a company's efficiency in generating profits from the equity invested by its shareholders. It demonstrates how well management is utilizing the capital provided to increase earnings and deliver value. OXY's current ROE is 16.6% compared with HES' ROE of 21.78%, the industry's ROE of 16.94%.
The Zacks Oil & Energy sector is a capital-intensive one, and huge investments are required at regular intervals to upgrade, maintain and expand operations. The usage of new evolving technology also requires investments. Occidental Petroleum's debt-to-capital currently stands at 40.64% compared with Hess Corporation's debt-to-capital of 41.48%.
Occidental Petroleum appears to be cheaper compared with Hess Corporation on trailing 12-month Enterprise Value/Earnings before Interest Tax Depreciation and Amortization (EV/EBITDA).OXY is currently trading at 4.87X, while HES is trading at 7.23X compared with its sector's 4.59X.
Last month, shares of Occidental Petroleum gained 4.5% compared with Hess Corporation's rally of 2.1%.
Image Source: Zacks Investment Research
Occidental Petroleum's persistent focus on Permian resources has been beneficial for the company. Nearly 83% of Occidental's production comes from its domestic assets. Stable international operation and ongoing reduction of debt will continue to act as a tailwind.International operations, particularly assets in Guyana, are a major source of oil and gas production for Hess Corporation. Based on the above discussion, we will suggest OXY, which carries a Zacks Rank #3 (Hold), should be in your oil and gas portfolio and avoid Hess Corporation, carrying a Zacks Rank #5 (Strong Sell) for the time being.You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hess Corporation (HES) : Free Stock Analysis Report
Occidental Petroleum Corporation (OXY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Gold's Rally Broke Down in May. It's Still Doing Better Than Stocks.
Gold just wrapped up its worst month since December, but don't count the yellow metal out just yet. Gold futures fell 0.5% to $3,288.90 per troy ounce in May to snap a four-month winning streak, with the metal marking its biggest monthly decline in five months, according to Dow Jones Market Data. Gold is still up 25.1% this year, far outpacing the S&P 500's 0.5% 2025 gain.
Yahoo
an hour ago
- Yahoo
COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down
The Cooper Companies, Inc. COO delivered second-quarter fiscal 2025 adjusted earnings per share (EPS) of 96 cents, which improved 11.5% year over year. The figure beat the Zacks Consensus Estimate of 93 cents by 3.2%. Operational improvements drove the bottom-line growth. GAAP EPS for the quarter was 44 cents, which remained flat year over year. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.) Revenues totaled $1 billion, up 6.3% year over year on a reported basis. The figure beat the Zacks Consensus Estimate by 0.7%. The quarterly revenues were up 7% year over year at constant exchange rate (CER) as well as on an organic basis. Robust performances of daily silicone hydrogel lenses, and office and surgical portfolio drove the top line in the fiscal second quarter. Despite beating estimates on both counts, shares of COO were down 4.9% during after-hours trading on May 29. The company's shares have lost 13% so far this year compared with the industry's decline of 0.8%. The S&P 500 Index was down 0.3% during the same period. Image Source: Zacks Investment Research COO conducts its business via two reportable segments — CooperVision ('CVI') and CooperSurgical ('CSI'). For the second quarter of fiscal 2025, the CVI segment's revenues totaled $669.6 million, up 5% year over year on a reported basis and 7% at CER as well as organically. This figure compares to our segmental projection of $668.7 million. Category-wise, CVI derives revenues from Toric and multifocal, Sphere and others. In the fiscal second quarter, Toric and multifocal revenues totaled $328.4 million, up 6% year over year on a reported basis, and up 7% organically as well as at CER. This figure compares to our projection of $326.3 million. Sphere, other revenues totaled $341.2 million, up 5% year over year on a reported basis and up 6% at CER as well as organically. This figure compares to our projection of $342.5 million. Geographically, CVI derives revenues from the Americas, Europe, and Asia Pacific. Americas revenues totaled $282.4 million, up 7% year over year on a reported basis and up 8% at CER and organically. The figure compares to our projection of $275.7 million. EMEA revenues amounted to $248.6 million, up 5% year over year on a reported basis and up 6% at CER and organically. This figure compares to our projection of $253 million. Asia Pacific revenues in the fiscal first quarter totaled $138.6 million, up 3% year over year organically and 5% at CER. This figure compares to our projection of $140 million. The CSI segment's revenues totaled $332.7 million, which moved up 8% on a reported basis, 9% at CER and 7% organically. This figure compares to our projection of $326.7 million. Category-wise, CSI derives revenues from Office and surgical, and the fiscal first quarter, Office and surgical revenues totaled $205.8 million, up 13% on a reported basis and at CER, and up 10% organically. This figure compares to our projection of $193.4 million. Fertility revenues in the fiscal first quarter amounted to $126.9 million, up 3% on a reported basis, up 4% organically and up 2% at CER year over year. This figure compares to our projection of $133.4 million. In the quarter under review, Cooper Companies' adjusted gross profit rose 2.4% to $681.9 million. The adjusted gross margin expanded 100 basis points (bps) to 68%. We had projected 65.9% of gross margin for the fiscal second quarter. Selling, general and administrative expenses rose 4.9% to $399 million. Research and development expenses increased 17% to $45.5 million. Adjusted operating costs totaled $432.4 million, reflecting a 5.6% increase from the prior-year quarter's level. Adjusted operating profit totaled $249.5 million, reflecting an 11% increase from the year-earlier quarter's level. The adjusted operating margin in the fiscal second quarter expanded 100 bps to 25%. COO exited second-quarter fiscal 2025 with cash and cash equivalents of $116.2 million compared with $100.9 million at the end of the fiscal first quarter. Total debt at the end of the fiscal second quarter was $2.77 billion compared with $2.59 billion at the end of the fiscal first quarter. Cooper Companies has updated its outlook for fiscal 2025. The company expects revenues to be in the range of $4,107-$4,146 million (prior $4,080-$4,158 million), suggesting an organic improvement of 5-6% from the prior-year figure. The Zacks Consensus Estimate is pegged at $4.12 billion. COO expects the CVI segment's revenues to be in the range of $2,759-$2,786 million (previously $2,733-$2,786 million), suggesting an organic improvement of 6-7% from the year-earlier registered figure. The company anticipates the CSI segment's revenues to be in the range of $1,347-$1,359 million (prior $1,347-$1,372 million), indicating an organic improvement of 3.5-4.5% from the year-earlier figure. For the entire fiscal year, adjusted EPS is expected to be in the $4.05-$4.11 range. The Zacks Consensus Estimate is pegged at $3.98. The Cooper Companies, Inc. price-consensus-eps-surprise-chart | The Cooper Companies, Inc. Quote The Cooper Companies exited the fiscal second quarter on a strong note. Both its earnings and sales beat expectations. CooperVision's robust growth was driven by continued strength in MyDay and Clarity daily silicone hydrogel lenses, as well as in Biofinity and Avaira in the frequent replacement category. MyDay saw robust global demand, including successful launches like MyDay Energys in Canada. Clarity's redesigned multifocal variant performed well, while Biofinity maintained its position as the world's most-worn contact lens. MySight, COO's myopia management solution, grew 35%, bolstered by a new pricing strategy and a major private label deal. A free trial program is expected to support continued adoption, with a temporary revenue dip in the fiscal third quarter followed by stronger growth in the fourth quarter. CooperSurgical's outperformance was led by strength in the office and surgical segment, including the ALLY uterine manipulator and obp Surgical's retractors. PARAGARD sales surged 18% due to pre-buying ahead of a price increase, but are projected to decline in the third quarter and remain flat in the fourth quarter. Fertility revenues faced macro pressures in Asia, and tighter clinic spending weighed on growth. Tariffs are anticipated to have a $4 million impact this year, with a potential 3% earnings drag in fiscal 2026 if unmitigated. Despite macro softness and lower market growth assumptions, COO continues to gain share through innovation, capacity expansion, and commercial execution, positioning it well for the remainder of the fiscal year. COO currently has a Zacks Rank #3 (Hold). Some better-ranked stocks from the same medical industry are GENEDX HOLDINGS WGS, CVS Health CVS and Cencora COR. GENEDX, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 336% for 2025. You can see the complete list of today's Zacks #1 Rank stocks here. WGS' earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 145.82%. WGS' shares have lost 6.1% so far this year. CVS Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 12.2% for 2025. CVS' earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 18.08%. CVS' shares have risen 42% year to date. Cencora, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 16.7% for 2025. COR's earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.00%. Its shares have gained 30.4% so far this year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates
The Cooper Companies (COO) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.23%. A quarter ago, it was expected that this surgical and contact lens products maker would post earnings of $0.92 per share when it actually produced earnings of $0.92, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates three times. The Cooper Companies , which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $1 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 0.67%. This compares to year-ago revenues of $942.6 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. The Cooper Companies shares have lost about 12.9% since the beginning of the year versus the S&P 500's gain of 0.1%. While The Cooper Companies has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for The Cooper Companies: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.05 on $1.07 billion in revenues for the coming quarter and $3.98 on $4.12 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the broader Zacks Medical sector, Plus Therapeutics (PSTV), is yet to report results for the quarter ended March 2025. This developer of cell therapies is expected to post quarterly loss of $0.17 per share in its upcoming report, which represents a year-over-year change of +77.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Plus Therapeutics' revenues are expected to be $1.85 million, up 10.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report Plus Therapeutics, Inc. (PSTV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
